氟伐他汀对高血压患者血压、C-反应蛋白和血管内皮功能的影响

Effect of fuvastatin on blood pressure,hsCRP and vascular endothelial function in hypertension

目的探讨氟伐他汀对高血压患者血压、C-反应蛋白和血管内皮功能的影响。方法将80例高血压患者随机分成对照组(n=40)和氟伐他汀组(n=40),对照组给予贝那普利和硝本地平控释片,氟伐他汀组在此基础上加用氟伐他汀。观察治疗前及治疗后4周两组反应性充血时肱动脉内径变化率(FMD)、血清高敏C-反应蛋白(hsCRP)、一氧化氮(NO)、血浆内皮素(ET)、6-酮-前列腺素FI(6-keto-PGFI)和血栓素B(2TXB2)情况。结果治疗4周后,氟伐他汀组FMD由治疗前的8.20%±0.72%,上升至12.39%±0.97%(P<0.05);NO浓度也较治疗前显著升高(47.67±4.36pg/mlvs52.94±4.40pg/ml,P<0.01);ET浓度较治疗前降低(31.31±2.47pg/mlvs24.33±2.45pg/ml,P<0.01)。对照组上述参数治疗前后均无明显变化(P>0.05)。对照组治疗后收缩压明显下降(P<0.05),舒张压和hsCRP无明显变化(P>0.05);氟伐他汀组治疗后血压、血清hsCRP均有所下降(P<0.05),与对照组比较,差异有统计学意义(P<0.05)。结论氟伐他汀可以降低高血压患者hsCRP浓度,调控NO/ET平衡,改善血管内皮功能,从而降低血压。

Objective To investigate the effects of fuvastatin on blood pressure, hsCRP vascular endothelial function in patients with hypertension. Methods 80 patients with hypertension were randomly recruited and divided into two groups： Fuvastatin group（n=40）and the control group （n=40）.Plasma levels of hsCRP, NO,ET, 6-keto-PGFIα, TXB2 and diastolic functions of humeral artteries（measured by high-resolution）were measured at baseline and 4 weeks later. Results Compare to baseline leuel ,the flow-mediated dilation was significantly increased from（8.20±0.72） % to （ 12.39±0.97） % （P 〈 0.05） in fuvastatin group after 4 weeks therapy.Their plasma NO was significantly increased （47.67±4.36pg/ml vs 52.94±4.40pg/ml, P 〈 0.01） and plasma ET significantly reduced （31.31±2.47pg/ml vs 24.33±2.45 pg/ml,P 〈 0.01 ） after 4 week fuvastatin therapy. The parameters mentioned above in the control group had no significant differences（P 〉 0.05）. The bood pressure and plasma hsCRP reduced in bott groups after 4-week therapy .However, the fuvastatin group was markedly superior to the control group （P 〈 0.05）. Conclusions Fuvastatin improves the vascular endothelial dependent diastolic function in patients with hypertension by reducing plasma hsCRP and regulating the balance of plasma NO/ET, further reducing the bood pressure of patients with hypertension.